Rationale and Design of EMPOWER, a Pragmatic Randomized Trial of Automated Hovering in Patients With Congestive Heart Failure

被引:10
|
作者
Mehta, Shivan J. [1 ,2 ,3 ]
Volpp, Kevin G. [1 ,2 ,3 ]
Asch, David A. [1 ,2 ,3 ]
Goldberg, Lee R. [1 ,2 ]
Russell, Louise B. [1 ,2 ]
Norton, Laurie A. [1 ,2 ]
Iannotte, Lauren G. [1 ,2 ]
Troxel, Andrea B. [4 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Dept Hlth Policy & Med Eth, Philadelphia, PA 19104 USA
[3] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA
[4] NYU, Sch Med, Dept Populat Hlth, Div Biostat, New York, NY USA
来源
关键词
disease management; health care cost; heart failure; morbidity; mortality; HEALTH; HOSPITALIZATION; MANAGEMENT; ADHERENCE; OUTCOMES; RISK; MORTALITY; PATTERNS; SURVIVAL; MODEL;
D O I
10.1161/CIRCOUTCOMES.118.005126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Congestive heart failure is a major cause of morbidity, mortality, and cost. Disease management programs have shown promise but lack firm evidence of effectiveness and scalability. We describe the motivation, design, and planned analyses of EMPOWER (Electronic Monitoring of Patients Offers Ways to Enhance Recovery), a randomized clinical trial of an innovative intervention incorporating behavioral economic principles with remote monitoring technology embedded within a healthcare system. METHODS AND RESULTS: EMPOWER is an ongoing, pragmatic, randomized clinical trial comparing usual care to an automated hovering intervention that includes patient-level incentives for daily weight monitoring and diuretic adherence combined with automated feedback into the clinical care pathway, enabling real-time response to concerning clinical symptoms. Identification of eligible patients began in May 2016, and implementation of the intervention is feasible. Trial processes are embedded into existing clinical pathways. The primary outcome is time to readmission for any cause. Cost-effectiveness analyses are planned to evaluate the healthcare costs and health outcomes of the approach. CONCLUSIONS: The EMPOWER trial incorporates leading-edge approaches in human motivation, derived from behavioral economics, with contemporary technology to provide scale and exception handling at low cost. The trial is also implemented within the naturalized environment of a health system, as much as possible taking advantage of the existing journeys of patients and workflows of clinicians. A goal of this pragmatic design is to limit resource utilization and also to test an intervention that would need minimal modification to be translated from research into a new way of practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Pragmatic Design of Randomized Clinical Trials for Heart Failure Rationale and Design of the TRANSFORM-HF Trial
    Greene, Stephen J.
    Velazquez, Eric J.
    Anstrom, Kevin J.
    Eisenstein, Eric L.
    Sapp, Shelly
    Morgan, Shelby
    Harding, Tina
    Sachdev, Vandana
    Ketema, Fassil
    Kim, Dong-Yun
    Desvigne-Nickens, Patrice
    Pitt, Bertram
    Mentz, Robert J.
    JACC-HEART FAILURE, 2021, 9 (05) : 325 - 335
  • [2] Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program
    Troxel, Andrea B.
    Asch, David A.
    Mehta, Shivan J.
    Norton, Laurie
    Taylor, Devon
    Calderon, Tirza A.
    Lim, Raymond
    Zhu, Jingsan
    Kolansky, Daniel M.
    Drachman, Brian M.
    Volpp, Kevin G.
    AMERICAN HEART JOURNAL, 2016, 179 : 166 - 174
  • [3] Pragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementation
    Victoria-Castro, Angela M.
    Martin, Melissa
    Yamamoto, Yu
    Ahmad, Tariq
    Arora, Tanima
    Calderon, Frida
    Desai, Nihar
    Gerber, Brett
    Lee, Kyoung A.
    Jacoby, Daniel
    Melchinger, Hannah
    Nguyen, Andrew
    Shaw, Melissa
    Simonov, Michael
    Williams, Alyssa
    Weinstein, Jason
    Wilson, Francis P.
    CLINICAL CARDIOLOGY, 2022, 45 (08) : 839 - 849
  • [4] Rationale and Design of PURE: A Randomized Controlled Trial to Evaluate Peritoneal Ultrafiltration with PolyCore™ in Refractory Congestive Heart Failure
    Gronda, Edoardo
    Gallieni, Maurizio
    Pacileo, Giuseppe
    Capasso, Giovambattista
    Wei, Lee-Jen
    Trepiccione, Francesco
    Heidempergher, Marco
    Bonomini, Mario
    Zimarino, Marco
    Divino-Filho, Jose Carolino
    Di Liberato, Lorenzo
    Caracciolo, Maria Michela
    Masola, Valentina
    Prosdocimi, Tommaso
    Iacobelli, Massimo
    Vitagliano, Caterina
    Arduini, Arduino
    KIDNEY & BLOOD PRESSURE RESEARCH, 2024, 49 (01): : 860 - 870
  • [5] Kyoto Congestive Heart Failure (KCHF) study: rationale and design
    Yamamoto, Erika
    Kato, Takao
    Ozasa, Neiko
    Yaku, Hidenori
    Inuzuka, Yasutaka
    Tamaki, Yodo
    Kitai, Takeshi
    Morimoto, Takeshi
    Taniguchi, Ryoji
    Iguchi, Moritake
    Kato, Masashi
    Takahashi, Mamoru
    Jinnai, Toshikazu
    Ikeda, Tomoyuki
    Nagao, Kazuya
    Kawai, Takafumi
    Komasa, Akihiro
    Nishikawa, Ryusuke
    Kawase, Yuichi
    Morinaga, Takashi
    Kawashima, Tsuneaki
    Motohashi, Yasuyo
    Kawato, Mitsunori
    Toyofuku, Mamoru
    Sato, Yukihito
    Kuwahara, Koichiro
    Shioi, Tetsuo
    Kimura, Takeshi
    ESC HEART FAILURE, 2017, 4 (03): : 216 - 223
  • [6] The pediatric randomized carvedilol trial in children with chronic heart failure: Rationale and design
    Shaddy, RE
    Curtin, EL
    Sower, B
    Tani, LY
    Burr, J
    LaSalle, B
    Boucek, MM
    Mahony, L
    Hsu, DT
    Pahl, E
    Burch, GH
    Schlencker-Herceg, R
    AMERICAN HEART JOURNAL, 2002, 144 (03) : 383 - 389
  • [7] Randomized controlled trial of exercise training in patients with congestive heart failure (EXERT)
    McKelvie, RS
    Teo, KK
    McCartney, N
    Roberts, RS
    Costantini, LA
    Montague, TJ
    Humen, DP
    Guyatt, GH
    Yusuf, S
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) : 508A - 509A
  • [8] Rationale and design of a randomised trial of intravenous iron in patients with heart failure
    Kalra, Paul R.
    Cleland, John G. F.
    Petrie, Mark C.
    Ahmed, Fozia Z.
    Foley, Paul W. X.
    Kalra, Philip A.
    Lang, Ninian N.
    Lane, Rebecca E.
    Macdougall, Iain C.
    Pellicori, Pierpaolo
    Pope, Michael T. B.
    Robertson, Michele
    Squire, Iain B.
    Thomson, Elizabeth A.
    Ford, Ian
    HEART, 2022, 108 (24) : 1979 - 1985
  • [9] The WHICH? trial: rationale and design of a pragmatic randomized, multicentre comparison of home- vs. clinic-based management of chronic heart failure patients
    Stewart, Simon
    Carrington, Melinda J.
    Marwick, Thomas
    Davidson, Patricia M.
    Macdonald, Peter
    Horowitz, John
    Krum, Henry
    Newton, Phillip J.
    Reid, Christopher
    Scuffham, Paul A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (08) : 909 - 916
  • [10] Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial
    Agner, E
    Sygehus, H
    Aguinaga, L
    Andersen, HB
    Arnold, JMO
    Atie, J
    Bagger, H
    Battler, E
    Bellorini, M
    Berning, J
    Bernstein, V
    Bishop, W
    Boccardo, DA
    Bonet, J
    Borggrefe, M
    Borts, D
    Bose, S
    Buxton, A
    Caeiro, AA
    Capone, RJ
    Carlos, J
    Jorge, M
    Caspi, A
    Chandrashekar, Y
    Connors, S
    Constance, C
    Corrado, G
    Costi, P
    Coutu, B
    Davies, T
    de Paola, AAV
    Delage, F
    Demers, C
    De Roy, L
    Dion, D
    Dionne, N
    Dong, R
    Dorian, P
    Dubner, S
    Egstrup, K
    Eldar, M
    Forzami, T
    Fruergaard, P
    Gadsboll, N
    Garand, M
    Garcia-Palmieri, MR
    Gardner, MG
    Gebhardt, V
    Giannetti, N
    Giannoccaro, J
    AMERICAN HEART JOURNAL, 2002, 144 (04) : 597 - 607